
Lindsey Wang
Articles
-
Jun 28, 2024 |
mdpi.com | Tomasz Tabernacki |Lindsey Wang |David C. Kaelber |Rong Xu
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
May 31, 2024 |
preprints.org | Tomasz Tabernacki |Lindsey Wang |David C. Kaelber |Rong Xu
PreprintArticleVersion 1This version is not peer-reviewedVersion 1: Received: 30 May 2024 / Approved: 31 May 2024 / Online: 31 May 2024 (08:10:28 CEST)Tabernacki, T.; Wang, L.; Kaelber, D.; Xu, R.; Berger, N. A. Non-Insulin Antidiabetic Agents and Lung Cancer Risk in Drug-Naive Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study. Preprints 2024, 2024052086. https://doi.org/10.20944/preprints202405.2086.v1Tabernacki, T.; Wang, L.; Kaelber, D.; Xu, R.; Berger, N. A.
-
Mar 14, 2024 |
jamanetwork.com | Lindsey Wang |Rong Xu |David C. Kaelber |Nathan A Berger
Key PointsQuestion Is there clinical evidence supporting the potential benefits of glucagon-like peptide receptor agonists (GLP-1RAs) for the prevention of 13 obesity-associated cancers (OACs)?
-
Dec 27, 2023 |
youhavetoliveyour.life | Hayley Gleeson |Lindsey Wang |Pamela Davis |Nathan A Berger
Australian Broadcasting Corporation Other / Mixed Journalist Study Other / Mixed Article on a study Journalist Article on a study Journalist Other / Mixed Group of professionals Study Other / Mixed Johns Hopkins Bloomberg School of Public Health Other / Mixed Other / Mixed University of Auckland News and Opinion Article on a study Other / Professional Article on a study Other / Mixed...
-
Dec 7, 2023 |
jamanetwork.com | Lindsey Wang |william wang |David C. Kaelber |Nathan A Berger
GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are approved by the US Food and Drug Administration for treating type 2 diabetes (T2D).
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →